feed,title,long_url,short_url
Investors,Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst,https://www.investors.com/news/technology/sarepta-stock-gene-therapy-duchenne-muscular-dystrophy-first-quarter/,https://da.gd/XbCpeP
